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SUMMARY
Vaccine escape variants of hepatitis B virus (HBV) have been identified world-wide. A
mathematical model of HBV transmission is used to investigate the potential pattern of
emergence of such variants. Attention is focused on The Gambia as a country with high
quality epidemiological data, universal infant immunization and in which escape mutants after
childhood infections have been observed. We predict that a variant cannot become dominant
for at least 20 years from the start of vaccination, even when using a vaccine which affords no
cross protection. The dominant factor responsible for this long time scale is the low rate of
infectious contacts between infected and susceptible individuals (we estimate the basic
reproduction number of hepatitis B in The Gambia to be 1–7). A variant strain that achieves
high prevalence will also take many years to control, and it is questionable whether emergence
will be identifiable by sero-surveillance until of high prevalence. The sensitivity of the model
predictions to epidemiological and demographic factors is explored.
INTRODUCTION
Hepatitis B virus (HBV) variants have been reported
to arise in immunized individuals in three situations:
(i) after liver transplantation, despite treatment with
monoclonal antibodies against surface antigen (anti-
HBs) and hyper-immunoglobulin (HBIG) treatment
[1–3], (ii) neonatal infections, despite HBIG and}or
vaccination in the UK [4], Italy [5], Singapore [6],
Indonesia [7] and Japan [8], and (iii) horizontal
infections in young children despite vaccination in
The Gambia [9]. The 22 nm subviral surface antigen
peptides (HBsAg) used in the current vaccines (both
plasma derived and recombinant) produce a narrower
immune response than immunity following infection.
This has led to the possibility that a single amino acid
substitution in HBsAg can allow the virus to evade the
vaccine-induced immune response, allowing repli-
* Author for correspondence: J. N. Wilson, Department of Biol-
ogical Sciences, University of Warwick, Coventry CV4 7AL, UK.
cation within the vaccinated individual. Several such
substitutions have been reported: most commonly an
arginine instead of glycine at codon 145 (G145R), but
also substitutions at codons 144, 141 and 126. The
evasion of vaccine induced-immunity does not always
appear to be complete, however, as chimpanzees
vaccinated by the standard sub-unit vaccine remained
uninfected by challenge with the G145R variant [10].
This particular mutation has been identified in viruses
of different genotypes suggesting it has arisen inde-
pendently in different parts of the world. Indeed these
variants have been identified, infrequently, in the
absence of vaccination. However their emergence
raises serious concern only where universal vac
cination may provide an environment in which they
can replace the current HBV. The WHO is currently
promoting increased vaccine coverage not only in
countries with high HBsAg prevalence, but world-
wide [11].
This scenario provided the motivation for the
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construction and analysis of a mathematical model of
the transmission of HBV, the impact of vaccination
and the potential emergence of a vaccine escape
variant. A mathematical model is desirable in order to
identify the underlying epidemiological processes that
allow a novel pathogen to be transmitted more than
the wild-type and so become dominant, and also to
make projections of the predicted pattern and time
scale of this emergence. We focus on The Gambia as
representative of those countries with high HBV
transmission in Africa; one also with universal infant
immunization in which the occurrence of vaccine
escape mutants has been observed. The transmission
dynamics of HBV in The Gambia has previously been
modelled by Edmunds and colleagues [12]. We modify
their model into a two-strain structure similar to the
general two-strain model of acute childhood infections
presented by McLean [13]. The inclusion of the age-
dependent processes of transmission and carrier
generation, and realistic demography, represents a
significant development from that used in our prel-
iminary studies [14].
We initially present the results of a steady state
(long-term equilibrium) analysis which elucidates the
conditions of vaccination coverage, cross immunity
and relative transmissibility of variant to wild type,
which affect the emergence of a mutant strain. We
then explore the temporal patterns of emergence
predicted using the age-structured, compartmental
model, and assess the effect of a variety of factors on
the predicted outcome, including epidemiological and
demographic conditions typical of other HBV ende-
micity regions.
METHODS
Equilibrium model
The potential for the long term emergence of HBV
variants depends both on characteristics of the
vaccination programme and on the fitness of each
strain at the population level, as represented by the
basic reproduction number. The basic reproduction
number of strain 1 and 2 (R
!"
and R
!#
) is the average
number of secondary infections arising if one primary
infection were introduced into a wholly susceptible
population. Vaccine escape variants have not become
dominant (i.e. out-competed normal HBV) prior to
the introduction of HBV vaccines, suggesting the
variants have a reduced replication competence. There
is no direct experimental evidence of the size of this
reduction, so a range of values are examined; we
assume R
!#
flaR
!"
, and examine afl 0–1. Due to the
stimulation of a broader immune response (i.e. in
addition to anti-HBs) recovery from infection is
assumed to produce immunity to both strains.
In a vaccinated population the competitive outcome
between strains is determined by the reproduction
numbers under vaccination, R
v"
and R
v#
. These are
lower than the respective R
!
’s because, due to
vaccination, the whole population is not susceptible.
For example, an individual may make 5 potentially
infectious contacts during their period of infect-
iousness (R
!
fl 5), but if 3 out of every 5 people are
effectively immunized then only 2 contacts will
actually result in transmission (R
v
fl 2). A vaccination
programme can be summarized by its coverage (m), the
vaccine-induced protection (u) and the cross-immu-
nity (c) of the vaccine. Therefore vaccine impact is u
against wild-type infection and cu against variant
infection. After a period under this programme, and
in the absence of infection, the proportion susceptible
to the wild-type (strain 1) approaches (1fium) and to
the variant (strain 2), (1ficum). The reproduction
numbers of strain 1 and 2 under vaccination are
therefore as shown in equations (1) and (2) :
R
v"
flR
!"
(1fium), (1)
R
v#
flaR
!"
(1ficum). (2)
Elimination from a population occurs when R
vi
! 1.
Equations (3) and (4) show the critical vaccination
coverages (m!
i
), required to reduce R
vi
below unity and
thus achieve elimination:
m!
"
fl
1
u 01fi
1
R
!"
1 , (3)
m!
#
fl
1
cu 01fi
1
aR
!"
1 . (4)
By equating equations (1) and (2) we can also calculate
a competitive threshold, m
eq
, at which point the two
strains have identical reproduction numbers and
would coexist (equation 5) :
m
eq
fl
1fia
u(1fiac)
. (5)
Equation (5) also provides a fairly accurate appr-
oximation of the threshold coverage for the domi-
nance of strain 2 and the exclusion of strain 1. With
values of m greater than m
eq
, the vaccine escape variant
has a higher reproduction number than the wild-type
(R
v#
"R
v"
) and the wild-type is out-competed and
does not persist. However this system of wild-type and
vaccine-escape variant is not symmetrical and at
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values of m less than m
eq
, the vaccine escape variant
may still coexist with the wild-type. This occurs
because the variant is able to infect vaccinated
individuals in addition to the fully susceptible indi-
viduals who can be infected by either strain. Equation
(5) therefore does not represent the threshold cond-
itions for the persistence of strain 2 because strain 2
can persist when R
v"
"R
v#
. As discussed in the legend
to Figure 2, this zone of coexistence (described by m$
#
)
can be approximated by considering the fraction of
the population remaining susceptible to the variant
(x$
#
) when the wild-type has infected sufficient indi-
viduals to reduce the effective reproduction number of
strain 1 to unity. The thresholds describing the area of
coexistence (m
eq
and m$
#
), however, are only appr-
oximations and coexistence may still occur in situ-
ations in which m" m
eq
and}or m! m$
#
.
Dynamic model
We base our dynamic model on a deterministic, age-
structured, compartmental model of HBV transm-
ission in The Gambia developed by Edmunds and
colleagues [12]. As such, our results rely on the
validity of this model to accurately describe and
explain wild-type HBV epidemiology. The original
model was modified to accommodate a second strain
– the vaccine escape variant. The two strains are
assumed to act identically except in their ability to
infect vaccinated individuals and in their relative
transmissibility. Mathematical details of the modified
model are given in the Appendix and the key elements
are described in the following sections. The human
population is represented by seven compartments as
shown in Figure 1, and is structured by gender (g), age
(a) and time (t) (Appendix (a)). The compartments
represent susceptible (Xg(a, t)) and vaccinated (Vg(a,
t)) individuals, individuals with primary infection of
either strain 1 or 2 (Yg
"
(a, t) and Yg
#
(a, t)), chronic
carriers of strain 1 or 2 (Cg
"
(a, t) and Cg
#
(a, t)) and
individuals recovered from either infection (Zg(a, t)).
Strain 1 represents the current HBV and strain 2 a
vaccine-escape variant. The population is structured
by bi-monthly age-cohorts in order to include age-
and gender-specific birth and death rates, age-
dependent mixing rates (and resultant age-related
forces of infection), and the strong age-dependence in
the probability with which a primary infection may
become chronic [15]. Deaths are removed from all
classes at a rate, lg(a) which allows for specific age-
and gender-stratified demographic data. Alternatively
Infection Carriage
Recovery
Recovery
Z
CarriageInfectionV Y2 C2
C1Y1
InfectionBirths
X
Fig. 1. Compartmental model structure with individuals
susceptible (X), vaccinated (V), currently with primary HBV
infection of either strain 1 or strain 2 (Y
"
and Y
#
), with
chronic infection of either strain 1 or strain 2 (C
"
and C
#
)
and those immune to re-infection by either strain (Z). Strain
1 represents the current circulating HBV strain and strain 2
the vaccine escape variant. Deaths are removed from each
compartment. The vaccine is assumed to be delivered near
to the time of birth, with the fraction not successfully
vaccinated entering the susceptible class (X). Transmission
can occur through vertical, sexual or horizontal routes. The
model is age structured in order to incorporate the strong
age-dependence in the probability of becoming a carrier
following infection, this and other parameters are described
in the text and Appendix.
type I or II mortality schedules can be accommodated
(type I mortality assumes all individuals survive until
the average expectancy of life (L), type II mortality
assumes individuals die at a constant death rate
equivalent to 1}L [16]). There is no infection-induced
mortality. Births enter the youngest male and female
age-cohort at a rate m(a) dependent on the number of
females of child-bearing age and assuming a 1:1 sex-
ratio of births. We assume no maternally derived
antibody protection in the new-born. A fraction (m) of
births enter the vaccinated class and the remainder
(1fim) enter the susceptible class (see Appendix (b)).
Transmission
The infectious population is calculated as the sum of
primary infections and carriers, Yg
s
(a, t)›gCg
s
(a, t), for
each strain s ; the reduced viral load of carriers (C ) is
assumed to make them less infectious than acute cases
(Y ) by a factor g. This method is consistent with
Edmunds and colleagues [12] and is chosen in
preference to that of McLean & Blumberg [17], in
which e-antigen-positive (HBeAg+) carriers are assu-
med to be fully infectious and HBeAg− carriers
uninfectious. The per capita rates at which susc-
eptibles of one or other sex become infected by one or
other strain (the forces of infection, kg
s
(i, t)), are a
function of the size of this infectious population which
mix with the susceptibles of each age class i. They are
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Table 1. Summary of model parameters
Symbol Parameter Base-line parameter estimates References
Ng(a, t) Present population size 748000 (The Gambia) [23]
lg(a) Death rate for gender (g) and age (a) Table 3 [23]
m(a) Birth rate of females of age a Table 3 [23]
a Relative transmission coefficients of strains 0–9 No data
j Sexual transmission coefficient for strain 1
(aj for strain 2)
0–574 per partnership [12]
um Rate of partner change 2–3 per year (male) (female rate modified for
changes in sex ratio, see Appendix (c))
[12]
b Vertical transmission coefficient for strain 1
(ab for strain 2)
0–71 [12]
p(a) Probability of becoming a carrier 0–885 for afl 0–6 months
exp (fi0–645 a!–%&&) for a" 6 months
[15]
g Relative infectiousness of chronic and
primary infection
0–16 [12]
c Recovery rate (acute) 4–8 per year (average duration 2–5 months) [12]
r Recovery rate (chronic) 0–023 per year (average duration 43–5 years) [12]
Q Mutation probability 0–001 per infection [18, 26]
m Proportion of population covered by
vaccination programme
0–8
u Degree of vaccine-induced protection 0–9 [20]
c Cross-immunity of vaccine 0–5 No data
kg
s
(i, t) Force of infection (per person incidence) see Appendix (d) [12]
calculated for horizontal (parenteral) and sexual
transmission for ages over 15 years and as horizontal
transmission alone for ages under 15. Horizontal
transmission is modelled by a density-independent
term i.e. of the form bI}N, where I is the infectious
population, N is the total population and b is a matrix
which determines the pattern of mixing between the
different age-groups of susceptible and infectious
individuals and the probability of transmission foll-
owing contact (see Anderson and May, [16]). Sexual
transmission is also modelled by a density-indep-
endent term though with age-independent, heter-
osexual mixing between susceptibles and infectious
individuals over 15 years old. These terms are
presented in full in Appendix (c). The model could be
simplified by amalgamating horizontal and sexual
transmission but we retain the distinction to be
consistent with the model of Edmunds and colleagues
[12].
To accommodate a second strain the forces of
infection due to normal virus or its mutated variant
are modified by a mutation term Q, in a similar way
to McLean and Nowak [18]. Q is the probability that
an infectious contact with strain 1 results in an
infection with strain 2, and vice versa. Thus the total
force of infection (K) due to strain s acting on
susceptibles (of sex g and age a) is defined as:
Kg
s
(a, t)fl (1fiQ)kg
s
(a, t)›Qkg
s«
(a, t), (6)
in which kg
s«
(a, t) is the force of infection for strain 1 or
2 of which a proportion (1fiQ) have not mutated and
kg
s
(a, t) is the force of infection for the alternative
strain of which a proportion Q have mutated.
Vaccination can also be thought to modify the forces
of infection. The degree of protection of the vaccine
against strain 1 is u and against strain 2, cu [19]. Thus
c is a cross-immunity term reflecting the relative
protection of the vaccine against strain 2. The
vaccinated class remain partly susceptible to infection,
but experience a force of infection reduced by a factor
(1fiu) for strain 1 and by (1ficu) for strain 2.
Vertical or perinatal transmission is modelled by a
fraction (b) of births from the infectious population of
each strain, entering the primary infection class of the
youngest age-cohorts ; b is assumed to be affected by
mutation and vaccination in the same way as
horizontal and sexual transmission (see Appendix
(b)).
Recoery
Individuals were assumed to recover from primary
infection at a rate c and from chronic infection at a
rate r, for both strains, where c(r. The probability
that a primary infection becomes chronic is modelled
by an exponentially declining age-dependent function
p(a) as described in Edmunds and colleagues [15] and
summarized in Table 1. Recovery from primary and
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Table 2. Demographic parameters for The Gambia [23]
Initial population Death
size (thousands)* rates Birth
Age rates
(a years) Nf(a, 0) Nm(a, 0) lf(a) lm(a) m(a)
! 1 13–4 13–2 0–184 0–215 0–000
1–4 53–6 52–8 0–028 0–024 0–000
5–9 51–0 52–0 0–049 0–044 0–000
10–14 42–0 42–0 0–042 0–044 0–000
15–19 36–0 35–0 0–033 0–038 0–200
20–24 33–0 32–0 0–021 0–022 0–293
25–29 30–0 29–0 0–019 0–019 0–285
30–34 25–0 26–0 0–033 0–022 0–222
35–39 21–0 24–0 0–035 0–018 0–161
40–44 17–0 20–0 0–041 0–033 0–077
45–49 14–0 16–0 0–040 0–044 0–040
50–54 12–0 13–0 0–034 0–043 0–000
55–59 9–0 9–0 0–053 0–068 0–000
60–64 7–0 7–0 0–054 0–058 0–000
65–69 5–0 4–0 0–067 0–102 0–000
70–74 2–0 2–0 0–161 0–139 0–000
75–80 0–0 0–0 0–467 0–469 0–000
* f, female ; m, male.
chronic infections is again assumed to produce
immunity to reinfection by either strain.
Parameter estimation
The efficacy of the current HBV vaccine against the
normal HBV type has been estimated in The Gambia
to be between 93% and 956% [20]. The values are
chosen to represent an estimate of the ‘degree’ of
protection (u) of the vaccine, setting ufl 0–9, which
measures the reduction in the force of infection
experienced by vaccinees [19]. If the vaccine affords
the same degree of protection against the variant as
against normal HBV, the cross-immunity term, c,
would be equal to 1; if half as much protection then
cfl 0–5; and if the vaccine provides no cross-
protection then cfl 0. We examine universal infant
vaccine programmes with coverage m, in which the
vaccine is assumed to ‘take’ in all vaccinated
individuals (i.e. we ignore the small proportion who
do not seroconvert) and in which the ‘degree’ of
protection is assumed not to wane [21].
Edmunds and colleagues [12] estimated the age-
and gender-stratified birth and death rates for The
Gambia [23] and the rates of recovery from acute and
chronic HBV infection. The probability of becoming
a carrier was estimated by Edmunds and colleagues
[15]. The model’s parameters are summarized in
Tables 1 and 2. Edmunds and colleagues [12] also
estimated the force of infection in different age-groups
from serological data from The Gambia. These
estimates allow the calculation of the transmission
matrices (b) as discussed in Anderson and May [24].
For the purposes of estimating age-specific effective
contact rates it is necessary to discretize age into n
classes from the n estimates of the force of infection.
Edmunds and colleagues [12] showed that five age
classes were sufficient to capture the epidemiology of
HBV in The Gambia. The pattern of mixing chosen is
also consistent with the pattern used by Edmunds and
colleagues [12] : this assumes equal levels of tran-
smission among and between one age group and all
younger age groups. Thus transmission within the
youngest age group (0–1 year olds) has a unique value,
whilst adults (over 15 years old) are assumed to mix
(non-sexually) with all the other age groups equally.
Matrices for realistic population growth and station-
ary population situations are shown in Appendix (d).
Model implementation and output
The system of partial differential equations was coded
in FORTRAN and solved under the parameter values
given in Table 1 using a Sun processor (with a time
step of 1 day). Vaccination was assumed to occur once
the model had settled to equilibrium (after 200 years).
If a population grows in size, the proportions of
individuals in each age cohort change. Thus for
300 J. N. Wilson, D. Nokes and W. F. Carman
simulations of a growing population in The Gambia
the model was run to equilibrium without vaccination
to determine the proportions of individuals in each
infection class, these proportions were scaled to the
known present-day age-distribution of The Gambia
and vaccination introduced at time zero.
The incidence of each strain per 100000 people was
calculated as the force of infection, Kg
s
(a, t), multiplied
by the total susceptible population (including vacc-
inees), summed over one year (t) across all ages (a)
and for both genders (g), as a proportion of the total
population Ng(a, t), scaled to 100000.
Incidence of strain s per 100000 per yearfl
R
t
R
a
R
g
Kg
s
(a, t) [Xg(a, t)›(1ficu)Vg(a, t)]
(7)
‹
100000
R
t
R
a
R
g
Ng(a, t)
(where cfl 1 for strain 1).
The prevalence of carriers at time t was calculated
as the sum of the carrier classes across all ages and
both genders as a proportion of the total population.
Prevalence of carriers
of strain s at time tfl
R
a
R
g
Cg
s
(a, t)
R
a
R
g
Ng(a, t)
(8)
RESULTS
The results of the study are in two parts. Initially the
long term equilibrium or steady state results are
examined (i.e. many years after the introduction of a
vaccination programme) before looking at the temp-
oral dynamics prior to equilibrium using the age- and
time-structured model described above.
Equilibrium model analysis
Analysis of the equilibrium model involves (i) esti-
mating an R
!
for wild-type HBV infection (ii)
estimating the degree of protection (u) of the vaccine
against the wild-type and then (iii) exploring the effect
of different values of cross-immunity (c), coverage (m)
and relative transmissibility (a). Edmunds [25] esti-
mates R
!
fl 5 using an age-independent model of
serological HBV data in The Gambia. The same data
described by an age-dependent model will have a lower
R
!
as the force of infection and the probability of
carriage decreases in older age groups [16]. In the
results of our age-dependent model we estimate R
!
to
be approximately 1–7 and we therefore use this
estimate in the equilibrium analysis. The precise
calculation of R
!
for our dynamic model is beyond the
scope of this paper.
The conditions defined by equations (3) and (4)
(assuming ufl 0–9 and R
!"
fl 1–7), produce the graphs
in Figure 2a and b. It is clear from these graphs that
both strains are only eliminated at high levels of
coverage (m) and cross-immunity (c). At higher a and
hence higher R
!#
(Fig. 2a) the variant is able to out-
compete the normal HBV under a greater range of
parameters. At lower a (Fig. 2b), R
!#
is lower and so
strain 2 can be eliminated with lower coverage and
with a less cross-protective vaccine. Thus there is a
balance between the advantage to the variant of the
vaccination programme subduing the normal HBV
(its competitor) and the possibility that the vacc-
ination eliminates the variant as well.
Although reproduction numbers can largely dete-
rmine the eventual pattern of dominance, they are not
indicative of the time-scale or magnitude of the
emergence of a variant. This is determined by the rate
at which susceptibles to strain 1 and 2 accumulate.
Individuals susceptible to the variant include both
unvaccinated and vaccinated individuals in whom the
vaccine is, to a greater or lesser degree (as defined by
c) ineffective. The incidence of the variant infections
cannot increase until the susceptible threshold is
crossed ie. the effective reproduction number exceeds
unity (the respective threshold proportions are 1}R
!"
and 1}R
!#
[16]). From then the rate of spread will be
determined by the transmission coefficients, i.e. the
rates of effective contacts within and between age
classes in the population.
Dynamic model analysis
The results of the age-structured model are presented
in Figures 3–6. Figure 3a shows the projected
incidence of normal HBV and vaccine escape variant
infections through time after vaccination in The
Gambia, at different values of vaccine cross-immunity
(c), with vaccine coverage at 80%. If cfl 0 then the
variant becomes dominant, achieving an incidence
equivalent to the normal HBV strain (reduced by a
factor approximately equal to a, the ratio of the
reproductive capacities of the two strains, R
!#
}R
!"
)
under the baseline model and parameter assumptions.
If c" 0–4 then both strains are eliminated.
In Figure 3b the vaccine coverage is varied from 0
to 100%, with a fixed cross-immunity term (cfl 0–5),
and the equilibrium prevalence of carriers (after 1000
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Fig. 2. Four equations (m!
"
, m!
#
, m
eq
and m$
#
) determine four potential outcomes of vaccination: wild-type and variant eradicated
(A), wild-type (B), or variant (C) exist alone or both strains coexist (D). The elimination thresholds (m!
"
and m!
#
) are calculated
for wild-type and vaccine-escape variant respectively in a vaccinated population where coverage is m and the impact of the
vaccine is u (ufl 0–9) against the wild-type (strain 1) and cu against the variant (strain 2). These are assumed to be ‘all or
nothing’ protection parameters. For example when cfl 0–5 the vaccine is half as effective against the variant as it is against
the wild-type. A competitive threshold is approximated by m
eq
, which also acts as a persistence threshold for the wild-type.
An area of coexistence is approximated by considering the fraction of the population remaining susceptible to the variant
(x$
#
) when the wild-type has infected sufficient individuals to reduce the effective reproduction number of strain 1 to unity.
Thus a fraction x$
"
fl 1}R
!"
are susceptible to wild-type infection (and to the variant) and a further (1fic)um are susceptible
to the variant only. Thus x$
#
fl 1}R
!"
›(1fic)um. By setting R
!#
x$
#
equal to unity we can calculate a threshold vaccination
coverage for the persistence of the variant : m$
#
fl (1fia)}aR
!"
r(1fic). R
!"
is assumed to be 1–7 and R
!#
flaR
!"
, i.e. the relative
transmissibility of wild-type to variant is a : (a) afl 0–9, (b) afl 0–5.
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Fig. 3. (a) The predicted incidence of HBV infection per 100000 per year (as calculated by equation (7)) after a vaccination
programme with 80% coverage introduced at time zero when infection is at a stable equilibrium (under baseline parameter
settings, Table 1). The vaccine was assumed to provide 90% protection against the normal HBV strain (ufl 0–9). The
protection against the variant was reduced by a factor c, and the different lines describe simulations with c varying from 0
to 1. The dotted lines represent the normal HBV and the solid lines represent the variant, with values of c decreasing from
the lower line upwards, all other parameters are base-line. Even with a vaccine which afforded no cross-protection (cfl 0)
the variant is predicted not to become dominant for over 20 years. (b) The predicted prevalence of carriers at equilibrium
(i.e. the steady state prevalence following many years of vaccination, as calculated by equation (8)) at different vaccine
coverage levels, with all other parameters base-line. The dotted line represents the normal HBV and the solid line represents
the vaccine escape variant. The cross-protection term (c) was assumed to be 0–5. The variant achieves dominance at
intermediate coverage levels but is eliminated at high coverage levels.
years) is plotted. The variant achieves dominance at
intermediate levels of coverage being itself eliminated
at high coverage levels (as in Fig. 2). For higher and
lower values of c (i.e. greater or less cross-immunity)
the peak prevalence of strain 2 shifts, aligning with
higher or lower coverage levels respectively ; pred-
ictably this peak is higher at low values of c and lower
when cross-immunity is high.
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Fig. 4. The predicted incidence per 100000 per year for
different values of a, the relative transmissibility of variant
to wild-type HBV. The solid lines represent the variant at
different values of a. The lower dotted line represents the
wild-type when afl 1–0, the other dotted line represents the
wild-type at all other values of a. When afl 1–0 the
incidence of wild-type is lower and the incidence of variant
is higher at timefl 0 than for other simulations, hence the
slightly more rapid elimination. With afl 1–0 the variant
would eventually attain equal incidence to the wild-type, but
vaccination is introduced before this equilibrium is reached.
At values of a% 0–6 the variant does not emerge. (coverage,
mfl 0–8; cross-immunity, cfl 0–0; other parameters base-
line).
Sensitivity
The dynamics of the original model [12, 25] appear
relatively robust to realistic parameter variation, e.g.
recovery rates (r and c), the relative infectiousness of
acute and carriers (g) and the form of the transmission
matrix (b). We explore the predicted patterns of
emergence of vaccine escape variants under different
values of the parameters describing the relative
transmissibility of the variant (a), the mutation term
(Q) and the demographic parameters (birth and death
rates).
Relatie transmissibility
The relative transmissibility of wild-type and variant
(a) influences the force of infection of the variant.
Figure 4 shows model simulations at different values
of a. In this scenario if a& 0–7 the variant emerges to
a steady state the magnitude of which is lower at lower
values of a. If a% 0–6 the variant does not emerge at
all even though mfl 0–8 and cfl 0–0. The simulation
when afl 0–6 therefore provides a method to estimate
R
!"
. The simulation is on the threshold of emergence
suggesting R
v#
is close to unity, hence, with R
v#
fl 1, a
fl 0–6 and cfl 0–0, we can estimate R
!"
fl 1}0–6
(equation (2)). Therefore we use R
!"
fl 1–7 in the
equilibrium analysis. Differences between the dyna-
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Fig. 5. The predicted incidence per 100000 per year for
different values of Q, the probability of an infection with
strain 1 resulting in an infection with strain 2 and vice versa,
i.e. the chance of mutation per infection. The solid lines
represent the variant at different values of Q. The lower
dotted line represents the variant when Qfl 0–01, the other
dotted line represents the variant at all other values of Q.
The equilibrium prevalence of the variant before vaccination
(time! 0) is significantly higher with high mutation rates (Q
fl 0–01), and this reduces the time-scale of emergence of the
variant after vaccination as well as reducing the time-scale
for the elimination of the wild-type. (coverage, mfl 0–8;
cross-immunity, cfl 9–9; relative transmissibility afl 0–9;
other parameters base-line).
mic model predictions and those of the equilibrium
analysis may arise as the estimate of R
!"
fl 1–7 is an
approximation. Furthermore the equilibrium analysis
does not make predictions of steady state incidence.
The simulation with afl 1–0, i.e. when the variant has
the same force of infection (and basic reproduction
number) as the wild-type, differs from the other
simulations in Figure 4 because the prevalence of the
variant has not reached equilibrium (after 200 years)
when the vaccination programme starts (see timefl 0,
Fig. 4). Indeed this could be the situation with one or
more of the HBV variants observed today; the
particular mutation may have occurred long ago,
allowing vaccine escape of equivalent transmissibility
to normal HBV (i.e. equivalent viral replication), yet
the variant has still not attained equal prevalence by
the time the vaccination programme starts. An
estimate of the relative transmissibility of wild-type
and variant is thus required.
Mutation term
The mutation term, Q, was set at 0–001 i.e. 1 in every
1000 infections with wild-type HBV results in infection
with the variant and vice versa. It is difficult to
estimate this population level term from the mutation
rate of individual viruses (an estimate from the
hepadnaviridae is 2‹10−% base substitutions per site
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Fig. 6. The predicted prevalence of anti-HBc in the first year vaccinated cohort in The Gambia. We assume all classes in Fig.
1 are anti-HBc positive except susceptible (X) and vaccinated individuals (V). The different lines represent simulations with
the cross-protection term, c, varied from 0 to 1. The graph shows that a serological survey may not be able to discriminate
between values of c for 30–40 years after vaccination begins. The projected lines are not smooth as the cohort progresses
through different mortality age brackets, see Table 2 (coverage, mfl 0–8; relative transmissibility afl 0–9; other parameters
base-line).
per year [26]), in particular expressing the number of
variant virions in terms of infectiousness. But by
varying Q within a wide range, ie. 0–00001 and 0–01,
(all other parameters are base-line with cfl 0–0) the
rise in incidence is transposed approximately 15 years
earlier for each tenfold rise in the mutation rate (see
Fig. 5). The transition from one strain to another (as
in Fig. 3b) becomes more gradual if the mutation rate
is higher. Similar results can be produced by setting Q
to zero and introducing an equivalent equilibrium
number of individuals infected with the variant at the
beginning of the vaccine programme. Thus the
mutation term is important in determining the number
of people infected with the variant at the beginning of
the vaccine programme but less so once the epidemic
is underway. The model is very sensitive to this initial
prevalence and stochastic events may be important at
these low prevalence levels.
Birth and death rates
Simulations using realistic age-dependent birth and
death rates (yielding a C 3% annual population
growth rate in The Gambia) were compared with
simulations using a type II schedule (constant age-
independent rate of 0–025 for births and deaths and, as
birth rate equals death rate, zero population growth).
The simulations produced qualitatively similar but
quantitatively different results. Under high population
growth, the proportion of the population in the
younger age classes increases, thus increasing the
proportion of the population at high risk of infection
and carriage. In consequence the incidence and
prevalence of HBV is higher in these situations and
the emergence of a variant predicted to be faster than
within a slowly growing or stationary population.
Detection of variants by serological survey
From these results it appears that the most significant
unknown parameter in The Gambia is the cross-
immunity of the vaccine (c) which determines the
protection of the present vaccine against the dominant
variant, (though relative transmissibility is also impo-
rtant). Vaccine efficacy crucially needs to be evaluated
now in order to determine whether vaccine modi-
fications are required. Figure 6 shows projections for
the prevalence of anti-HBc observable in those
individuals vaccinated at birth in the first year of The
Gambian vaccination programme (with baseline
parameters and different values of c). The model
therefore follows a single age-cohort for 50 years and
predicts the fraction of the cohort that would be
positive for anti-HBc. This cohort is chosen as it is
likely to be the first to show signs of break-through
infections due to poor vaccine cross-immunity. We
assume all individuals who are or have been infected,
by either strain, are positive for anti-HBc. The
predictions seen in Figure 6 show that different levels
of vaccine-induced cross-immunity (c) cannot be
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easily distinguished for at least 30 or 40 years after the
start of vaccination. This long time-scale results partly
from the slow accumulation of people susceptible to
the variant and partly from the inherently low rate of
transmission of HBV. The emergence of a vaccine
escape variant, and a measurement of c, may thus
remain essentially hidden from anti-HBc serosur-
veillance for a number of decades. This result argues
for the use of highly specific assays, such as Poly-
merase Chain Reaction based techniques, in the
surveillance of populations for escape variants.
DISCUSSION
Conditions for emergence
This paper has examined the parameters which
determine whether, and how, a vaccine escape variant
of HBV will emerge. The characteristics of the vaccine
programme and the reproductive potential of the
viruses will together determine whether the variant
will be transmitted more than the normal HBV (Fig.
2) and whether either or both strains will persist. A
comparison between Figure 2a (when cfl 0–8) and
Figure 3 b reveals there is a considerable amount of
coexistence around the transition area from one strain
to another which is not altogether predicted in Figure
2a. The equilibrium analysis assumes Qfl 0–0, which
may be why the transition is more tightly constrained.
Previous mathematical models have been used to
describe coexistence in situations with super-infection
[27], strong density-dependent host-mortality [28] and
cross-species infection. Situations in which prior
infection with the virulent, wild-type strain is required
for infection by the variant, may also produce cycling
and hence a dynamic coexistence of strains [29].
Time scale of emergence
The analysis of effective reproduction numbers offers
limited insight ; the pattern of emergence will be
determined by the rate at which susceptible individuals
accumulate and by the magnitude of the transmission
coefficients and the particular demography and tran-
smission scenario in question. The results from the
dynamic model differ from those of McLean [13] as
strain 2 emerges monotonically over a long time
period, rather than as oscillatory epidemics. Although
HBV is highly contagious at the individual level, i.e.
there is a high probability of transmission per
infectious contact, the rate of such contacts is low.
Thus, even once the susceptibles (including vaccinated
individuals) have attained threshold levels, the time-
scale of emergence is in the order of decades, in
contrast to solely acute infections such as influenza,
where the time-scale of emergence may be in the order
of months or weeks. Another consideration is the
persistence of the pool of carriers infected by the wild-
type virus, these remain in competition with the
variant for susceptibles for many years, thus further
reducing the rate of emergence. The slow emergence is
also exaggerated because HBV variants are thought
only to evade vaccine-induced immunity whilst it
appears many influenza variants, for example, can
also evade infection-induced immunity, hence the
accumulation of individuals susceptible to HBV
variants will be slower than for influenza variants. It
should also be noted that the estimate of HBV R
!
fl
1–7 is very low relative to infections such as measles
and influenza, as well as being dominated by the
duration of infectiousness component rather than the
contact rate. The chronic nature of the infection
suggests that if an HBV variant is allowed to achieve
high prevalence (i.e. one noticeable from a serological
survey) it will take many decades to eliminate, even if
a more cross-reactive vaccine is introduced in the
future.
Sensitivity
The main result of this study depends on the
characteristic low transmission coefficient and long
average duration of infectiousness of HBV and is thus
robust to inaccuracies in other parameter estimates.
The disease relies on long term infections producing
new cases at a relatively low rate; hence variants will
emerge slowly and, if allowed to accumulate, will also
take a long time to eradicate. This is true even in The
Gambia where the force of infection is high and where
a youthful, growing population is suggested to speed
the spread of an HBV variant. In other parts of the
world, such as S.E. Asia, vertical transmission is
thought to be the dominant route by which individuals
become carriers. This is related to the strong age-
dependence in the probability of becoming a carrier
and the higher proportion of HBeAg positive carrier
mothers in S.E. Asia compared to, for example, Sub-
Saharan Africa. However pre-vaccination Taiwan
appears to have had the highest known incidence of
perinatal transmission, yet it has been estimated that
more than 60% of carriers were infected horizontally
[25]. Moreover if population growth is low and
families have on average only two children then it can
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be seen that vertical transmission alone can never
produce a R
!
greater than unity. Vertical transmission
is therefore expected to be more important in the
emergence of a variant in rapidly growing popu-
lations. Most cases of HBV vaccine escape have been
reported in neonates (though this may be a reporting
bias). Serological studies show vertical infection is a
minor transmission route in The Gambia compared to
horizontal transmission and model simulations show
that even if the probability of transmission from
carrier mother to infant (b) is high, this has little
impact on the dynamics of the emergence of a variant
(results not shown). Data were not available to model
the precise effect of vertical transmission in S.E. Asia.
Age-stratified serological surveys (prior to vaccin-
ation) are required to measure the proportion of the
population which is infected vertically (i.e. HBsAg
positive or HBcAg positive at birth) and provide an
estimate of the force of horizontal infection and hence
the relative importance of the vertical and horizontal
routes in these areas.
It appears that the magnitude or force of horizontal
infection in The Gambia is the lower limiting factor in
the time-scale of the emergence of a vaccine escape
variant. High endemicity countries clearly represent
situations in which emergence will be most rapid. In
intermediate and low endemicity countries the force
of horizontal infection will be lower and hence the rate
of emergence will be slower. The large number of
susceptible individuals in intermediate and low ende-
micity countries might be predicted to increase the
rate of spread of a variant, but the underlying
infectious contact rate (reflected in the transmission
rates) is so low that this is unlikely to be the case. In
countries with type I mortality (i.e. low infant and
adult mortality until close to the average life expe-
ctancy L), ageing populations and slow population
growth combine to produce proportionally fewer
APPENDIX. SUMMARY OF MODEL EQUATIONS (SEE TEXT FOR DETAILS)
(a) System of partial differential equations
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individuals in the high-risk, young-age groups, thus
reducing the prevalence of HBV carriers, the incidence
of infection and hence reducing the potential rates of
spread of variants.
Serological surveillance
The model suggests that anti-HBc serological surveys
of the first vaccinated cohort of neonates in The
Gambia may be unable to determine the effectiveness
of the vaccine against the variant for 30–40 years. If
assays for HBsAg are unable to detect all HBV
variants, carriers may accumulate undetected (except
through polymerase chain reaction based techniques)
and continue to remain a source of infection for
decades, with significant cost implications for unde-
veloped countries. Consequently it may be prudent to
err on the side of caution and assume that the current
vaccines are not sufficiently cross-reactive.
The key areas for development should therefore
include (i) an estimation of the cross-immunity of the
vaccine, (ii) estimation of the relative transmissibility
of variant and wild-type (for example by measuring
relative rates of viral replication), (iii) the development
of surveillance strategies capable of detecting emer-
gent variants at an early stage and (iv) the deve-
lopment and implementation of vaccines designed
with a reduced risk of selecting for variants : probably
with a wider epitope range specifically inducing
neutralizing antibodies against the commonest vacc-
ine-associated variants.
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(b) Birth terms
The birth terms (including vaccination, vertical transmission and mutation) entering the youngest age-cohorts
of classes X, V, Y
"
and Y
#
are shown below; the sex ratio is assumed to be 1:1, i.e. half the births are male and
half female.
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(c) Transmission terms
The horizontal (p) and sexual (q) transmission components of the force of infection, k, are shown below:
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The function age(j) corresponds to the age-class upper limits, in years, of the five age classes used in (Appendix
(d)) expressed as bimonthly cohorts with a maximum life expectancy of 80 years (i.e. afl 1–480). The gender g«
represents the alternate gender to g. Sexual transmission is assumed only to occur in those over 15 years old (a
" 90; ifl 5). The rate of partner change for each gender g is ug. The female rate is adjusted to compensate for
changes in sex ratio caused by the different age-dependent death rates of males and females [12]. The per
partnership rate of transmission is k
"
for wild-type HBV (strain 1). Both the sexual and horizontal transmission
of the variant is reduced by a, so k
#
flak
"
and b
#
(i, j)flab
"
(i, j). The overall force of infection, k
g
s
(i, t), is
modified by mutation as shown in equation (6).
(d) ‘Who acquires infection from whom’ and force of infection estimates
1. Estimates of the forces of infection for The Gambia [12] :
Age class (i) 1 2 3 4 5
Age (years) 0–1 1–5 5–10 10–15 15–80
kg(i, t) 0–159 0–144 0–116 0–089 0–030
Matrices of the transmission coefficients b
"
(i, j) were calculated from the forces of infection using a particular
‘who acquires infection from whom’ or WAIFW matrix [16] :
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(a) 3% population growth (b) 0% population growth (type II mortality)
icj 1 2 3 4 5 icj 1 2 3 4 5
1 14–13 6–80 4–42 3–11 0–84 1 25–78 10–78 6–61 4–47 1–02
2 6–80 6–80 4–42 3–11 0–84 2 10–78 10–78 6–61 4–47 1–02
3 4–42 4–42 4–42 3–11 0–84 3 6–61 6–61 6–61 4–47 1–02
4 3–11 3–11 3–11 3–11 0–84 4 4–47 4–47 4–47 4–47 1–02
5 0–84 0–84 0–84 0–84 0–84 5 1–02 1–02 1–02 1–02 1–02
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